Clinical Trial Detail

NCT ID NCT03225547
Title Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors University of Chicago
Indications

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

Therapies

Mifepristone + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST